These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15878591)

  • 1. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
    Papapetropoulos S; Argyriou AA
    Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
    [No Abstract]   [Full Text] [Related]  

  • 2. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 4. (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
    Knoll J
    Biomed Pharmacother; 1996; 50(6-7):315-7. PubMed ID: 8952875
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Parkinson's disease.
    Bergus G
    J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.
    Kamakura K; Mochizuki H; Kaida K; Hirata A; Kanzaki M; Masaki T; Nakamura R; Motoyoshi K
    Parkinsonism Relat Disord; 2004 Jun; 10(4):235-42. PubMed ID: 15120098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An artist's view of drug-induced hallucinosis.
    Ebersbach G
    Mov Disord; 2003 Jul; 18(7):833-4. PubMed ID: 12815666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Ben-Shlomo Y; Lees A;
    Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tactile hallucinations induced by trihexyphenidyl in a patient with Parkinson's disease].
    Funakawa I; Jinnai K
    Rinsho Shinkeigaku; 2005 Feb; 45(2):125-7. PubMed ID: 15782612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 11. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 13. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
    Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M
    No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects.
    Prescrire Int; 2003 Oct; 12(67):179. PubMed ID: 14619897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease.
    Gondim Fde A; Costa HA; Taunay TC; de Oliveira GR; Ferreira JM; Rola FH
    Mov Disord; 2010 Jul; 25(10):1505-6. PubMed ID: 20629118
    [No Abstract]   [Full Text] [Related]  

  • 16. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hallucinatory symptoms in Parkinson's disease during treatment with anti-parkinsonian drugs].
    Nagano O; Takauchi S; Nishitani H; Miyoshi K
    Rinsho Shinkeigaku; 1986 May; 26(5):464-70. PubMed ID: 3742899
    [No Abstract]   [Full Text] [Related]  

  • 18. Hallucinations in Parkinson's disease: the clinical syndrome.
    Goetz CG
    Adv Neurol; 1999; 80():419-23. PubMed ID: 10410750
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
    Stryjer R; Klein C; Treves TA; Rabey JM
    Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.